Search

everythinglearnresearchcommunity

for

Search:↓

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

A 20-year-old male is experiencing worsening diffuse thinning despite using topical minoxidil, topical finasteride with minoxidil, oral finasteride, stemoxydine, and pyrilutimide. He is seeking support and advice as he struggles with the mental and physical challenges of hair loss treatments.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

The conversation discusses GT20029 as a potential cure for hair loss and includes information on specific treatments used. Minoxidil, finasteride, and RU58841 are mentioned as related treatments.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

How Pyrilutamide, a hair loss treatment, has improved texture and regrowth of hair without any side effects for users, who are encouraged to post progress photos.

Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

Botox injections increase hair density in patients with androgenetic alopecia. Combining Botox with finasteride yields even better results.

A 22-year-old male experiencing hair thinning and loss, possibly due to seborrheic dermatitis or low vitamin D, is cautious about using minoxidil or finasteride due to heart palpitations and high blood pressure. Suggestions include using ketoconazole shampoo to control inflammation and focusing on treating the dermatitis first.

The user has experienced significant hair thinning despite using 2.5 mg minoxidil for 2 years. Other users suggest adding finasteride or dutasteride and consulting a dermatologist for a proper diagnosis.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. User feedback suggests 2-deoxy-D-ribose is ineffective.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The user switched from minoxidil to a homemade 2-deoxy-d-ribose gel and noticed no hair fall after two weeks, despite stopping minoxidil. The gel includes water, 2-deoxy-d-ribose, vegetable glycerine, 2-phenoxyethanol, sodium alginate, and rosemary oil, and the user reports healthier-feeling hair.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.